1. Home
  2. BOC vs PBYI Comparison

BOC vs PBYI Comparison

Compare BOC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$14.19

Market Cap

435.7M

Sector

N/A

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$7.87

Market Cap

403.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
PBYI
Founded
2009
2010
Country
United States
United States
Employees
N/A
179
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
435.7M
403.6M
IPO Year
2010
2011

Fundamental Metrics

Financial Performance
Metric
BOC
PBYI
Price
$14.19
$7.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
101.9K
323.2K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$114,376,348.00
$27,685,000.00
Revenue This Year
$5.79
N/A
Revenue Next Year
$4.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.64
N/A
52 Week Low
$10.52
$3.04
52 Week High
$15.22
$8.75

Technical Indicators

Market Signals
Indicator
BOC
PBYI
Relative Strength Index (RSI) 51.23 45.30
Support Level $13.95 $7.64
Resistance Level $14.66 $7.83
Average True Range (ATR) 0.31 0.37
MACD -0.05 -0.08
Stochastic Oscillator 15.48 13.16

Price Performance

Historical Comparison
BOC
PBYI

About BOC Boston Omaha Corporation

Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: